Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 61Sarcoma 36Breast 29Other hematologic neoplasm 26Gynecologic 16Gastrointestinal 14Other solid neoplasm 13CNS 10Genitourinary 9Tumor-Agnostic 6Thoracic 5Plasma cell 5Dermatologic 5Myeloid 4Endocrine 2Classical hematology 2NET 1Head & Neck 1

Conditions

Neuroendocrine Tumors 1Neoplasms 1

Interventions

Everolimus 10lutetium Lu 177 dotatate 7Magnetic Resonance Spectroscopy 7pasireotide 4Specimen Handling 3Positron Emission Tomography Computed Tomography 3Nivolumab 3Ga(III)-DOTATOC 3Fluorodeoxyglucose F18 3(177)Lu-DOTA-EB-TATE 3olaparib 2gallium Ga 68 dotatate 2amino-acid, glucose, and electrolyte solution 2Temozolomide 2Lutetium-177 2Ipilimumab 2FAPI-46 2veliparib 1vandetanib 1trifluridine tipiracil drug combination 1toripalimab 1tislelizumab 1talazoparib 1surufatinib 1romidepsin 1peposertib 1pembrolizumab 1pelcitoclax 1pegfilgrastim 1lanreotide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Doxorubicin × NET × Clear all
NCT01970540 2020-03-09

Study Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid Tumors

PharmaMar

Phase 1 Completed
122 enrolled 19 charts
EndocrineNET

Neoplasms, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡